Latest news and press releases about Nautilus Biotechnolgy, Inc. (NAUT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Price
| Price | $0.97 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.06 |
| EV / EBITDA | -2.63 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -37.58% |
| Return on Invested Capital | -39.50% |
| Return on Assets | -34.55% |
| Gross Margin | -919.47% |
| Operating Margin | -33043.68% |
| Net Margin | -29747.89% |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · IMRX · PYXS
Explore sector: Healthcare · Biotechnology
More sections of NAUT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks